Spravato has not been the "game-changer" for treating depression that it was touted as being. The market remains wide open for psilocybin (and other psychedelics).
A major IPO can be expected to attract a lot of new attention (and capital) to the psychedelic drug industry.
Novamind Ventures' new CMO has led over 100 clinical trials and currently serves as a Coordinating Investigator for MAPS.
Champignon Brands advises that the BCSC has revoked its original cease trade order (June 19, 2020), but a replacement order remains in effect.
Certain large Mydecine shareholders have entered into a voluntary lock-up, covering 52,908,420 common shares.